En español
NIDA

Menu

Heroin

References

  1. Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013.
  2. Cicero, T.J.; Ellis, M.S.; and Surratt, H.L. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 367(2):187–189, 2012.
  3. National Institute on Drug Abuse. Epidemiologic Trends in Drug Abuse, in Proceedings of the Community Epidemiology Work Group, January 2012. Bethesda, MD: National Institute on Drug Abuse, 66.
  4. Pollini, R.A.; Banta-Green, C.J.; Cuevas-Mota, J.; Metzner, M.; Teshale, E.; and Garfein, R.S. Problematic use of prescription-type opioids prior to heroin use among young heroin injectors. Subst Abuse Rehabil 2(1):173–180, 2011.
  5. Lankenau, S.E.; Teti, M.; Silva, K.; Jackson Bloom, J.; Harocopos, A.; and Treese, M. Initiation into prescription opioid misuse amongst young injection drug users.Int J Drug Policy 23(1):37–44, 2012.
  6. Johnston, L.D.; O’Malley, P.M.; Bachman, J.G.; and Schulenberg, J.E. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2013. Bethesda, MD: National Institute on Drug Abuse, 2013. Available at www.monitoringthefuture.org
  7. American Psychiatric Association. Substance-Related and Addictive Disorders, in Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Washington, DC: American Psychiatric Publishing, 540–550, 2013.
  8. National Institute on Drug Abuse, Community Epidemiology Working Group. Epidemiologic Trends in Drug Abuse, in Proceedings of the Community Epidemiology Work Group, January 2014, Bethesda, MD: National Institute on Drug Abuse. In preparation.
  9. Waldhoer, M.; Bartlett, S.E.; and Whistler, J.L. Opioid receptors. Annu Rev Biochem 73: 953–990, 2004.
  10. Johnson, S.W.; and North, R.A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12(2):483–488, 1992.
  11. Goldstein, A. Heroin addiction: neurobiology, pharmacology, and policy. J Psychoactive Drugs 23(2):123–133, 1991.
  12. Wang, X.; Li, B.; Zhou, X.; Liao, Y.; Tang, J.; Liu, T.; Hu, D.; and Hao, W. Changes in brain gray matter in abstinent heroin addicts. Drug Alcohol Depend 126(3):304–308, 2012.
  13. Ignar, D.M.; and Kuhn, C.M. Effects of specific mu and kappa opiate tolerance and abstinence on hypothalamo-pituitary-adrenal axis secretion in the rat. J Pharmacol Exp Ther 255(3):1287–1295, 1990.
  14. Kreek, M.J.; Ragunath, J.; Plevy, S.; Hamer, D.; Schneider, B.; and Hartman, N. ACTH, cortisol and beta-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. Neuropeptides 5(1-3):277–278, 1984.
  15. Kreek, M.J.; Levran, O.; Reed, B.; Schlussman, S.D.; Zhou, Y.; and Butelman, E.R. Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. J Clin Invest 122(10):3387–3393, 2012.
  16. Chen, L.H.; Hedegaard, H.; and Warner, M. QuickStats: Number of Deaths from Poisoning, Drug Poisoning, and Drug Poisoning Involving Opioid Analgesics - United States, 1999–2010. Morbidity and Mortality Weekly Report 234, 2013.
  17. Magiorkinis, G.; Sypsa, V.; Magiorkinis, E.; Paraskevis, D.; Katsoulidou, A.; Belshaw, R.; Fraser, C.; Pybus, O.G.; and Hatzakis, A. Integrating phylodynamics and epidemiology to estimate transmission diversity in viral epidemics. PLoS Comput Biol 9(1):e1002876, 2013.
  18. Centers for Disease Control and Prevention. Viral Hepatitis Surveillance - United States, 2010. Atlanta, GA: Centers for Disease Control and Prevention, 2012.
  19. Nelson, P.K.; Mathers, B.M.; Cowie, B.; Hagan, H.; Des Jarlais, D.; Horyniak, D.; and Degenhardt, L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378(9791):571–583, 2011.
  20. Jones, H.E.; Kaltenbach, K.; Heil, S.H.; Stine, S.M.; Coyle, M.G.; Arria, A.M.; O’Grady, K.E.; Selby, P.; Martin, P.R.; and Fischer, G. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 363(24):2320–2331, 2010.
  21. Kraft, W.K.; Dysart, K.; Greenspan, J.S.; Gibson, E.; Kaltenbach, K.; and Ehrlich, M.E. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction 106(3):574–580, 2010.
  22. Lund, I.O.; Fischer, G.; Welle-Strand, G.K.; O’Grady, K.E.; Debelak, K.; Morrone, W.R.; Jones, H.E. A comparison of buprenorphine + naloxone to buprenorphine and methadone in the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes. Subst Abuse 7:61–74, 2013.
  23. Boyer, E.W. Management of opioid analgesic overdose. N Engl J Med 367(2):146–155, 2012.
  24. Coffin, P.O.; and Sullivan, S.D. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med 158(1):1–9, 2013.
  25. Compton, W.M.; Volkow N.D.; Throckmorton, D.C.; and Lurie, P. Expanded access to opioid overdose intervention: research, practice, and policy needs. Ann Intern Med 158(1): 65–66, 2013.

This page was last updated February 2014

​Research Reports

This series of reports simplifies the science of research findings for the educated lay public, legislators, educational groups, and practitioners. The series reports on research findings of national interest.

Featured Publication

Featured Publication

Drugs, Brains, and Behavior - The Science of Addiction

As a result of scientific research, we know that addiction is a disease that affects both brain and behavior.

Ordering Publications

Call 1-877-643-2644 or:

NIDA Drug Pubs